Drug or treatment

Blinatumomab clinical trials

• 35Clinical trials
• 22Countries

Newest trials

All recruiting trials (35)

• Blinatumomab plus low-dose donor cells after transplant for high-risk B-ALL

  This small, early-phase study tests whether giving blinatumomab with low-dose donor lymphocytes after allogeneic transplant is safe and helps long-term survival for people with high-risk B-ALL.

  Recruiting Phase 1 Chinese PLA General Hospital · Beijing · NCT07677878

• LP-118 in combination with standard therapy for newly diagnosed Ph+ ALL

  This study tests whether adding LP-118 to the standard therapy for adults with Philadelphia chromosome–positive ALL is safe and useful.

  Recruiting at 2 sites Phase 1 Wake Forest University Health Sciences · Charlotte, North Carolina and 1 other locations · NCT07614022

• MK-1045 versus blinatumomab for relapsed or refractory CD19-positive B-cell acute lymphoblastic leukemia

  This trial will test whether MK-1045 helps people with relapsed or refractory CD19-positive B-cell acute lymphoblastic leukemia more than the standard immunotherapy blinatumomab.

  Recruiting at 30 sites Phase 2/3 Merck Sharp & Dohme LLC · Toronto, Ontario and 29 other locations · NCT07570173

• Vaccine protection after blinatumomab in children with B-ALL

  This project will see if children and young adults (ages 1–21) with B-cell acute lymphoblastic leukemia who received blinatumomab keep protective immunity from routine childhood vaccines and whether revaccination restores immunity when levels are low.

  Recruiting at 2 sites Arkansas Children's Hospital Research Institute · Little Rock, Arkansas and 1 other locations · NCT07422337

• Asciminib in children and young adults with relapsed or refractory Ph+ or ABL-class Ph-like ALL

  This study tests asciminib in kids and young adults with relapsed or refractory Philadelphia-positive or ABL-class Ph-like ALL to see if it is safe and helps treat the leukemia.

  Recruiting at 4 sites Phase 1/2 Novartis · Sydney, New South Wales and 3 other locations · NCT07387926

• Subcutaneous blinatumomab treatment for adults with CD19-positive mixed phenotype acute leukemia

  This trial tests whether giving blinatumomab under the skin can help adults with CD19-positive mixed phenotype acute leukemia, including older or unfit newly diagnosed patients, those with measurable residual disease after remission, and those with relapsed or refractory disease.

  Recruiting Phase 2 West Virginia University · Morgantown, West Virginia · NCT07222579

• Erwinia asparaginase and venetoclax added to blinatumomab for relapsed/refractory CD19+ B‑ALL

  This will test whether adding recombinant Erwinia asparaginase and venetoclax to blinatumomab helps adolescents and adults (12–55) with CD19-positive relapsed or refractory B-cell acute lymphoblastic leukemia.

  Recruiting Phase 1 City of Hope Medical Center · Duarte, California · NCT07133997

• Blinatumomab consolidation for adults with B‑cell acute lymphoblastic leukemia

  This registry collects medical data on adults with B‑ALL who receive blinatumomab as consolidation to see how well it works and how safe it is in routine care.

  Recruiting at 5 sites Medical College of Wisconsin · Jacksonville, Florida and 4 other locations · NCT07117136

• Blinatumomab plus donor lymphocyte infusion to prevent relapse after transplant in high-risk Ph-negative B‑cell ALL

  This trial tests whether giving blinatumomab together with donor lymphocyte infusions can help prevent relapse in people aged 14–65 with high‑risk Philadelphia chromosome–negative B‑cell acute lymphoblastic leukemia after an allogeneic stem cell transplant.

  Recruiting Phase 2 First Affiliated Hospital of Zhejiang University · Hangzhou · NCT07105579

• TCRαβ‑depleted haploidentical stem cell graft with early memory T‑cell donor lymphocyte infusions and selective blinatumomab for pediatric and young adult blood cancers

  This will test whether giving a TCRαβ‑depleted haploidentical stem cell graft plus early CD45RA‑depleted memory T‑cell infusions, with selective use of blinatumomab for CD19+ disease, is safe for children and young adults undergoing transplant for high‑risk blood cancers.

  Recruiting Phase 1 St. Jude Children's Research Hospital · Memphis, Tennessee · NCT07052370

• Blinatumomab before allogeneic stem cell transplant for MRD‑negative high‑risk B‑cell ALL

  This test sees if a short course of blinatumomab given before an allogeneic stem cell transplant helps adults (18–65) with high‑risk, BCR::ABL1‑negative B‑cell ALL who are MRD‑negative to lower relapse and improve survival.

  Recruiting First Affiliated Hospital of Zhejiang University · Hangzhou, Zhejiang · NCT07003737

• Short-course blinatumomab treatment for B-ALL patients with measurable residual disease

  This study tests whether a short treatment with blinatumomab can help people with B-cell acute lymphoblastic leukemia who still have some cancer cells left after their initial treatment, before they get a stem cell transplant.

  Recruiting Phase 2 Hospital Universitario Dr. Jose E. Gonzalez · Monterrey, Nuevo León · NCT06886074

• Using blinatumomab to treat difficult cases of childhood lupus

  This study is testing if a medication called blinatumomab can help children with tough cases of lupus feel better and manage their symptoms.

  Recruiting at 2 sites Phase 1 The Children's Hospital of Zhejiang University School of Medicine · Hangzhou, Zhejiang and 1 other locations · NCT06789107

• Combining Blinatumomab with Reduced-dose Chemotherapy for B-ALL Treatment

  This study is testing a new treatment that combines Blinatumomab with lower doses of chemotherapy to see if it helps adults with a type of leukemia called precursor B-cell acute lymphoblastic leukemia feel better and achieve a complete response.

  Recruiting Phase 2 First Affiliated Hospital of Zhejiang University · Hangzhou, Zhejiang · NCT06742515

• Using Blinatumomab to treat children with resistant nephrotic syndrome

  This study is testing if a new drug called Blinatumomab can help children with tough-to-treat nephrotic syndrome feel better by reducing protein in their urine.

  Recruiting Phase 1 The Children's Hospital of Zhejiang University School of Medicine · Hangzhou, Zhejiang · NCT06607991

• Evaluating Blinatumomab for Pediatric B-Lymphoblastic Leukemia

  This study is testing if a new treatment called Blinatumomab can help children with newly diagnosed acute B-Lymphoblastic leukemia who didn't respond well to their first round of chemotherapy.

  Recruiting at 2 sites Phase 2/3 Shanghai Jiao Tong University School of Medicine · Hefei, Anhui and 3 other locations · NCT06607419

• Testing inebilizumab and subcutaneous blinatumomab in adults with active, treatment‑resistant lupus or refractory rheumatoid arthritis

  This trial tests inebilizumab for adults with active, treatment‑resistant lupus with nephritis and tests subcutaneous blinatumomab for adults with active, treatment‑resistant lupus (with or without nephritis) and for adults with active refractory rheumatoid arthritis.

  Recruiting at 48 sites Phase 2 Amgen · Scottsdale, Arizona and 57 other locations · NCT06570798

• Combining Blinatumomab and Venetoclax with Inotuzumab Ozogamicin for B-ALL Treatment

  This study is testing a new combination of three medications to see if it can help adults with newly diagnosed B-cell acute lymphoblastic leukemia live longer and healthier lives.

  Recruiting Phase 2 First Affiliated Hospital of Zhejiang University · Hangzhou, Zhejiang · NCT06554626

• Using blinatumomab with autologous stem cell transplant for B-cell leukemia treatment

  This study is testing a new treatment for adults with B-cell leukemia that combines a drug called blinatumomab with a stem cell transplant to see if it helps improve their chances of recovery.

  Recruiting Phase 1 The First Affiliated Hospital of Soochow University · Suzhou, Jiangsu · NCT06507514

• Using decitabine, venetoclax, and blinatumomab for maintenance therapy in B-ALL patients after stem cell transplant

  This study is testing a combination of three medications to see if they can help people with B-cell acute lymphoblastic leukemia stay in remission after a stem cell transplant.

  Recruiting Phase 2 The First Affiliated Hospital of Soochow University · Suzhou, Jiangsu · NCT06393985

• Using Blinatumomab for treating relapsed Acute B-cell Lymphoblastic Leukemia after transplantation

  This study is testing if a new treatment called Blinatumomab can help younger patients with relapsed Acute B-cell Lymphoblastic Leukemia feel better after a stem cell transplant.

  Recruiting Phase 4 The First Affiliated Hospital of Zhengzhou University · Zhenzhou, Henan · NCT06339775

• Combining venetoclax and blinatumomab with standard chemotherapy for infants with acute leukemia

  This study is testing whether adding two new treatments, venetoclax and blinatumomab, to standard chemotherapy can help infants with acute leukemia do better and stay cancer-free longer.

  Recruiting at 117 sites Phase 2 National Cancer Institute (NCI) · Birmingham, Alabama and 116 other locations · NCT06317662

• Combining blinatumomab and asciminib for treating a type of leukemia

  This study is testing if combining two drugs, blinatumomab and asciminib, can help people with a specific type of leukemia feel better and improve their chances of recovery.

  Recruiting at 2 sites Phase 1/2 M.D. Anderson Cancer Center · The Bronx, New York and 1 other locations · NCT06308588

• Using Brexucabtagene Autoleucel to treat B-cell Acute Lymphoblastic Leukemia after initial therapy

  This study is testing a new CAR-T cell therapy called brexucabtagene autoleucel to see if it can help people with B-cell acute lymphoblastic leukemia who haven't responded to other treatments.

  Recruiting Phase 1/2 M.D. Anderson Cancer Center · Houston, Texas · NCT06287229

• Comparing Blinatumomab with hyperCVAD for treating Philadelphia-negative B-ALL

  This study is testing if combining Blinatumomab with lighter chemotherapy can help young adults with a type of leukemia feel better and have fewer side effects compared to a standard treatment.

  Recruiting Phase 2 The First Affiliated Hospital of Soochow University · Suzhou, Jiangsu · NCT06250959

• Combining blinatumomab with dasatinib or imatinib plus chemotherapy for young people with Ph+ or ABL-class Ph-like B‑ALL

  This pilot will see if adding three cycles of blinatumomab and a continuous tyrosine kinase inhibitor (dasatinib or imatinib) to a modified chemotherapy plan helps children, adolescents, and young adults with Ph+ or ABL-class Ph-like B‑ALL stay in remission longer.

  Recruiting at 159 sites Phase 2 National Cancer Institute (NCI) · Birmingham, Alabama and 160 other locations · NCT06124157

• Comparing treatments for Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia

  This study tests whether Ponatinib or Imatinib, both with low-dose chemotherapy, can help adults with Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia feel better, and looks at how Blinatumomab can be used for those who respond well or not to these treatments.

  Recruiting at 81 sites Phase 2 Goethe University · Aachen and 84 other locations · NCT06061094

• New treatment approach for pediatric patients with relapsed B-cell leukemia

  This study is testing a new combination treatment for kids with relapsed B-cell leukemia to see if it helps them get better and live longer.

  Recruiting Phase 2 M.D. Anderson Cancer Center · Houston, Texas · NCT05645718

• Preventing neurotoxicity in leukemia treatment with intrathecal chemotherapy

  This study is testing if giving a specific chemotherapy directly into the spine can help protect the brain from side effects while treating adults with Acute Lymphoblastic Leukemia.

  Recruiting Phase 2 Northside Hospital, Inc. · Atlanta, Georgia · NCT05519579

• Blinatumomab treatment after specific stem cell transplant for high-risk leukemia

  This study is testing if a new treatment using blinatumomab after a special type of stem cell transplant can help children and young adults with high-risk leukemia stay in remission and live longer.

  Recruiting Phase 2 Medical College of Wisconsin · Milwaukee, Wisconsin · NCT04746209

• Blinatumomab versus blinatumomab plus nivolumab for first-relapse CD19+ B‑ALL

  This test sees if adding nivolumab to blinatumomab helps children and young adults (ages 1–30) with first-relapse CD19+ B‑cell acute lymphoblastic leukemia, including people with Down syndrome.

  Recruiting at 154 sites Phase 2 National Cancer Institute (NCI) · Birmingham, Alabama and 226 other locations · NCT04546399

• Inotuzumab ozogamicin and blinatumomab with optional ponatinib for CD22-positive B-cell acute lymphoblastic leukemia

  This trial will test whether inotuzumab ozogamicin followed by blinatumomab, with or without ponatinib, can help people with CD22-positive B-cell acute lymphoblastic leukemia who are newly diagnosed, have relapsed, or are refractory to prior therapy.

  Recruiting at 89 sites Phase 2 National Cancer Institute (NCI) · Birmingham, Alabama and 284 other locations · NCT03739814

• Combination treatment for BCR-ABL positive B-cell leukemia and chronic myeloid leukemia

  This study is testing a new combination treatment for people with BCR-ABL positive B-cell leukemia or chronic myeloid leukemia to see if it helps them feel better and works well with existing medications.

  Recruiting at 4 sites Phase 1 Dana-Farber Cancer Institute · Chicago, Illinois and 3 other locations · NCT03595917

• Combining blinatumomab, methotrexate, cytarabine, and ponatinib for treating certain types of leukemia

  This study is testing a new combination of four medications to see if it can help people with certain types of leukemia that have come back or didn't respond to previous treatments.

  Recruiting Phase 2 M.D. Anderson Cancer Center · Houston, Texas · NCT03263572

• Using blinatumomab, inotuzumab ozogamicin, and chemotherapy to treat B acute lymphoblastic leukemia

  This study is testing a new combination of two immunotherapy drugs and chemotherapy to see if it helps people with newly diagnosed B acute lymphoblastic leukemia live longer and stay cancer-free.

  Recruiting Phase 2 M.D. Anderson Cancer Center · Houston, Texas · NCT02877303

Quick answers

How many clinical trials of Blinatumomab are recruiting right now?

35, as of November 12, 2026. We update this list each time we refresh our data from ClinicalTrials.gov.

Where are these trials running?

In 22 countries. The most sites are in United States (19 trials), China (12 trials), Puerto Rico (4 trials), Australia (4 trials), Canada (3 trials). Each study page lists its sites and which ones are recruiting.

What phases are they in?

Phase 2: 18, Phase 1: 8, Phase 1/2: 3, Phase 2/3: 2. Trials with no phase listed are usually device, behavioural or observational studies.

How do I join one?

Open a study, check the "Is this trial a fit for you?" section, then contact the study team listed on the page. They will ask a few screening questions. Asking is free and does not commit you to anything. Talk it over with your doctor first.

Find the studies that fit you

A list is a starting point. Tell us your situation in your own words and we'll rank the studies that match and explain why. It's free and needs no account.

Describe your situation →